Methods of treating or preventing zika virus infection

Abstract

This document relates to methods and materials for treating a mammal having a Zika virus (ZIKV) infection. For example, a composition including one or more non-nucleoside RNA polymerase inhibitors can be administered to a mammal having, or at risk of developing, a ZIKV infection to treat the mammal

What is claimed is: 
     
         1 . A method for treating a mammal having a Zika virus (ZIKV) infection, said method comprising: administering to said mammal a composition comprising a non-nucleoside RNA polymerase inhibitor. 
     
     
         2 . The method of  claim 1 , wherein said mammal is a human. 
     
     
         3 . The method of  claim 1 , wherein said non-nucleoside RNA polymerase inhibitor can bind to a catalytic active site of an RNA-dependent RNA-polymerase (RdRp) of said ZIKV to inhibit ZIKV replication. 
     
     
         4 . The method of  claim 1 , wherein said non-nucleoside RNA polymerase inhibitor is 3-chloro-N-[({4-[4-(2-thienylcarbonyl)-1-piperazinyl]phenyl}amino)carbonothioyl]-1-benzothiophene-2-carboxamide (TPB). 
     
     
         5 . The method of  claim 1 , wherein said non-nucleoside RNA polymerase inhibitor has an inhibitory concentration 50 (IC 50 ) of from about 10 nM to about 200 nM. 
     
     
         6 . The method of  claim 1 , wherein said non-nucleoside RNA polymerase inhibitor has a cytotoxicity concentration 50 (CC 50 ) of from about 15 μM to about 25 μM. 
     
     
         7 . The method of  claim 1 , wherein said non-nucleoside RNA polymerase inhibitor has a selective index 50 (SI 50 ) of about 206. 
     
     
         8 . The method of  claim 1 , wherein said administering step is performed prior to said ZIKV infection or after said ZIKV infection. 
     
     
         9 . The method of  claim 1 , wherein said administering step is performed prior to said ZIKV infection and after infection said ZIKV infection. 
     
     
         10 . The method of  claim 1 , wherein said non-nucleoside RNA polymerase inhibitor is administered intraperitoneally, intravenously, intramuscularly, or subcutaneously. 
     
     
         11 . A method of preventing microcephaly in a fetus said method comprising: administering a composition comprising a non-nucleoside RNA polymerase inhibitor to a mammal pregnant with said fetus, wherein said mammal has a ZIKV infection. 
     
     
         12 . The method of  claim 11 , wherein said mammal is a human. 
     
     
         13 . The method of  claim 11 , wherein said non-nucleoside RNA polymerase inhibitor is 3-chloro-N-[({4-[4-(2-thienylcarbonyl)-1-piperazinyl]phenyl}amino)carbonothioyl]-1-benzothiophene-2-carboxamide (TPB). 
     
     
         14 . A method of treating an adult mammal having Guillain-Barre syndrome said method comprising: administering to said mammal a composition comprising a non-nucleoside RNA polymerase inhibitor, wherein said mammal has a ZIKV infection. 
     
     
         15 . The method of  claim 14 , wherein said mammal is a human. 
     
     
         16 . The method of  claim 14 , wherein said non-nucleoside RNA polymerase inhibitor is 3-chloro-N-[({4-[4-(2-thienylcarbonyl)-1-piperazinyl]phenyl}amino)carbonothioyl]-1-benzothiophene-2-carboxamide (TPB). 
     
     
         17 . A composition for reducing Zika virus (ZIKV) viremia within a mammal, said composition comprising a non-nucleoside RNA polymerase inhibitor. 
     
     
         18 . The composition of  claim 17 , wherein said non-nucleoside RNA polymerase inhibitor is 3-chloro-N-[({4-[4-(2-thienylcarbonyl)-1-piperazinyl]phenyl}amino)carbonothioyl]-1-benzothiophene-2-carboxamide (TPB). 
     
     
         19 . The composition of  claim 17 , wherein said non-nucleoside RNA polymerase inhibitor can bind to a catalytic active site of an an RNA-dependent RNA-polymerase (RdRp) of said ZIKV. 
     
     
         20 . The method of  claim 17 , wherein said non-nucleoside RNA polymerase inhibitor has an inhibitory concentration 50 (IC 50 ) of from about 10 nM to about 200 nM. 
     
     
         21 . The method of  claim 17 , wherein said non-nucleoside RNA polymerase inhibitor has a cytotoxicity concentration 50 (CC 50 ) of from about 15 μM to about 25 μM. 
     
     
         22 . The method of  claim 17 , wherein said non-nucleoside RNA polymerase inhibitor has a selective index 50 (SI 50 ) of about 206. 
     
     
         23 . The composition of  claim 17 , further comprising a pharmaceutically acceptable carrier.